Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Dose Dependency of Iatrogenic Glucocorticoid Excess and Adrenal Insufficiency and Mortality: A Cohort Study in England

Open access
Mebrahtu, Teumzghi F, Morgan, Ann W, Keeley, Adam, Baxter, Paul D, Stewart, Paul M, Pujades-Rodriguez, Mar · 2019 · The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Adrenal insufficiency and Cushing syndrome are known adverse events of glucocorticoids. However, no population estimates of dose-related risks are available. OBJECTIVE: To investigate dose-related risks of adrenal dysfunction and death in adults with six chronic inflammatory diseases treated with oral glucocorticoids. DESIGN AND SETTING: Retrospective, record-linkage, open-cohort study spanning primary and hospital care in England. PATIENTS: A total of 70,638 oral glucocorticoid users and 41,166 nonusers aged ≥18 years registered in 389 practices in 1998 to 2017. MAIN OUTCOME MEASURES: Incidence rates and hazard ratios (HRs) of diagnosed adrenal dysfunction and death. RESULTS: During a median follow-up of 5.5 years, 183 patients had glucocorticoid-induced adrenal insufficiency and 248 had glucocorticoid-induced Cushing syndrome. A total of 22,317 (31.6%) and 7544 (18.3%) deaths occurred among glucocorticoid users and nonusers, respectively. The incidence of all outcomes increased with higher current daily and cumulative doses. For adrenal insufficiency, the increases in HRs were 1.07 (95% CI: 1.04 to 1.09) for every increase of 5 mg per day and 2.25 (95% CI: 2.15 to 2.35) per 1000 mg of cumulative prednisolone-equivalent dose over the past year. The respective increases in HRs for Cushing syndrome were 1.09 (95% CI: 1.08 to 1.11) and 2.31 (95% CI: 2.23 to 2.40) and for mortality 1.26 (95% CI: 2.24 to 1.28) and 2.05 (95% CI: 2.04 to 2.06). CONCLUSION: We report a high glucocorticoid dose-dependent increased risk of adrenal adverse events and death. The low observed absolute risk of adrenal insufficiency highlights a potential lack of awareness and a need for increased physician and patient education about the risks of adrenal dysfunction induced by glucocorticoids.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2019-00153

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Study flow diagram and outcome identification. Eligibility inclusion criteria were a minimum of 1 year of registration in the CPRD practice, consent to data linkage, age ≥18 years, and a diagnosis of inflammatory bowel disease, systemic lupus erythematosus, polymyalgia rheumatica, giant cell arteritis, rheumatoid arthritis, and/or vasculitis before or during the study period (1 January 1998 to 15 March 2017). During periods of nonglucocorticoid exposure, 102 patients had adrenal insufficiency and 94 patients had Cushing syndrome diagnosed at a median of 52 [interquartile range (IQR): 31 to 79] d and 42 (IQR: 30 to 63) d, respectively, following glucocorticoid discontinuation. ADI, adrenal insufficiency; CS, Cushing syndrome; GC, glucocorticoid.
Figure 1. Study flow diagram and outcome identification. Eligibility inclusion criteria were a minimum of 1 year of registration in the CPRD practice, consent to data linkage, age ≥18 years, and a diagnosis of inflammatory bowel disease, systemic lupus erythematosus, polymyalgia rheumatica, giant cell arteritis, rheumatoid arthritis, and/or vasculitis before or during the study period (1 January 1998 to 15 March 2017). During periods of nonglucocorticoid exposure, 102 patients had adrenal insufficiency and 94 patients had Cushing syndrome diagnosed at a median of 52 [interquartile range (IQR): 31 to 79] d and 42 (IQR: 30 to 63) d, respectively, following glucocorticoid discontinuation. ADI, adrenal insufficiency; CS, Cushing syndrome; GC, glucocorticoid.CC BY · PubMed Central
Figure 2. Definition of time-variant oral glucocorticoid exposure variables. Inclusion criteria included a diagnosis of inflammatory bowel disease, systemic lupus erythematosus, polymyalgia rheumatica, giant cell arteritis, rheumatoid arthritis, and/or vasculitis before or during the study period (1 January 1998 to 15 March 2017). GC, glucocorticoid; PED, prednisolone equivalent dose.
Figure 2. Definition of time-variant oral glucocorticoid exposure variables. Inclusion criteria included a diagnosis of inflammatory bowel disease, systemic lupus erythematosus, polymyalgia rheumatica, giant cell arteritis, rheumatoid arthritis, and/or vasculitis before or during the study period (1 January 1998 to 15 March 2017). GC, glucocorticoid; PED, prednisolone equivalent dose.CC BY · PubMed Central
Figure 3. Time-variant cumulative and current dose-related oral glucocorticoid hazard ratios with 95% CIs for adrenal dysfunction by type of chronic inflammatory disease. (A) Adrenal insufficiency. (B) Cushing syndrome. Estimates are adjusted for prescribed inhaled, intra-articular, intramuscular, nasogastric, topical, and rectal glucocorticoids. HR, hazard ratio; IBD, inflammatory bowel disease; PMR/GCA, polymyalgia rheumatica and/or giant cell arteritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; VAS, vasculitis.
Figure 3. Time-variant cumulative and current dose-related oral glucocorticoid hazard ratios with 95% CIs for adrenal dysfunction by type of chronic inflammatory disease. (A) Adrenal insufficiency. (B) Cushing syndrome. Estimates are adjusted for prescribed inhaled, intra-articular, intramuscular, nasogastric, topical, and rectal glucocorticoids. HR, hazard ratio; IBD, inflammatory bowel disease; PMR/GCA, polymyalgia rheumatica and/or giant cell arteritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; VAS, vasculitis.CC BY · PubMed Central
Figure 4. Time-variant cumulative and current dose-related oral glucocorticoid hazard ratios for death by type of chronic inflammatory disease. Estimates are adjusted for prescribed inhaled, intra-articular, intramuscular, nasogastric, topical, and rectal glucocorticoids; baseline asthma; cancer; heart failure; chronic kidney disease; and inflammatory diseases (time-variant). All estimates were obtained among glucocorticoid users during the study period. HR, hazard ratio; IBD, inflammatory bowel disease; PMR/GCA, polymyalgia rheumatica and/or giant cell arteritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; VAS, vasculitis.
Figure 4. Time-variant cumulative and current dose-related oral glucocorticoid hazard ratios for death by type of chronic inflammatory disease. Estimates are adjusted for prescribed inhaled, intra-articular, intramuscular, nasogastric, topical, and rectal glucocorticoids; baseline asthma; cancer; heart failure; chronic kidney disease; and inflammatory diseases (time-variant). All estimates were obtained among glucocorticoid users during the study period. HR, hazard ratio; IBD, inflammatory bowel disease; PMR/GCA, polymyalgia rheumatica and/or giant cell arteritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; VAS, vasculitis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 75

Metadata

Authors
Mebrahtu, T. F., Morgan, A. W., Keeley, A., Baxter, P. D., Stewart, P. M., & Pujades-Rodriguez, M.
Affiliations
  • University of Leeds (GB)
  • Leeds Institute of Health Sciences, School of Medicine, University of Leeds, Leeds, United Kingdom
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2019-04-22
Volume
104
Issue
9
Pages
3757-3767
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2941172693
Cited by
75
References
35
Citations by year
2026: 7 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 8 · 2021: 10 · 2020: 17 · 2019: 4
FWCI
7.91
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
Funders
  • Medical Research Council (RO-115-2018-1061)
  • European Research Council (250271)
  • National Institute for Health Research (RGRMEX 107713, MIC-2016-015, NF-SI-0514-10090)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
glucocorticoid-induced adrenal insufficiency, dose-dependent risk, mortality, chronic inflammatory diseases, prednisolone-equivalent dose, cumulative glucocorticoid dose, adverse drug reactions, adrenal dysfunction, England, primary and hospital care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.